Patient Home Monitoring Corp.
TSX VENTURE : PHM

November 07, 2011 21:37 ET

Patient Home Monitoring (PHM) Announces October 2011 Growth Figures

SAN FRANCISCO, CALIFORNIA--(Marketwire - Nov. 7, 2011) - Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a company focused on in-home cardiology healthcare services, today announced monthly growth in terms of meters shipped during the month of October 2011.

Monthly Growth

October 2011 Meter Shipments

PHM shipped 177 meters in October 2011, the first month of fiscal 2012. Since PHM started announcing monthly growth figures 8 months ago, PHM has shipped an average of 162 meters per month.

At the end of each month, PHM classifies revenue into two components:

1. Existing Patient Services. PHM generates a recurring monthly revenue stream from enrolled weekly testers.
2. New Patient Enrollment. New patients add to the existing monthly revenue stream

Once enrolled, PHM ships a meter with an expected 5-year economic life to a patient. With this meter investment, PHM generates monthly recurring revenue by providing weekly monitoring services to the patient.

Understanding how many meters were shipped to newly enrolled patients each month is relevant for analyzing growth because shipment of a meter is a prerequisite to performing INR(1) tests eligible for reimbursement(2).

"We continue to enjoy robust demand within our niche for in-home services," said Dr. Jaime Gerber, PHM's CEO. "We are adding patients each month, increasing our annuity-based revenue and generating more cash inflow to finance growth each month. The key to our continued growth is our ability to purchase meters for patients as each meter placed directly generates an annuity cash flow from the patient. Therefore, our primary focus now is securing debt to acquire meters at a fast enough rate to keep up with our customer demand. While the current capital markets are challenging, we do have a business that can support borrowing for capital equipment. We intend to secure debt in the coming months to finance continued growth at this rate, or faster, into the years to come. "

Q3 2011 Q4 2011 Q1 2012
April May June July Aug Sept Oct
Meters Shipped 131 158 220 138 157 158 176
Running Average 131 144 169 161 160 160 162

About PHM

PHM is a healthcare services company focused on providing in-home testing for patients on blood thinner medications such as Coumadin® or warfarin. Medicare recently expanded reimbursement for in-home patient self testing (PST) of blood coagulation levels. PHM has a unique value proposition to cardiology groups that manage patients on blood thinners, focusing on systemization to enroll patients in PST. Current enrollment compliance levels may not be predictive of future enrollment compliance levels. This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, increasing revenue to their clinic while providing a higher standard of care for patients.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, changes in US healthcare laws, coverage or budgets, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

(1) International normalized ratio ("INR") tests are used as measures of current and future sales performance. Please refer to the "Non-GAAP Measures" section of PHM's MDA for further discussion on these operational measure

(2) Management does not mean to suggest or imply that shipment of meters is equivalent to revenue. Meter shipment is a prerequisite, but not a guaranty, of revenue. Management does not propose meter shipments as a non-GAAP financial measurement, because there is no simple reconciliation between meter shipment and GAAP revenue

Contact Information

  • Stanmore Capital Partners, Inc.
    Michael Dalsin
    Managing Director
    (323) 253-3055
    mpd@stanmorecap.com